The Leiomyoma drugs in development market research report provides comprehensive information on the therapeutics under development for Leiomyoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Leiomyoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Leiomyoma and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Leiomyoma by 16 companies/universities/institutes. The top development phase for Leiomyoma is preclinical with six drugs in that stage. The Leiomyoma pipeline has 14 drugs in development by companies and one by universities/ institutes. Some of the companies in the Leiomyoma pipeline products market are: Foresee Pharmaceuticals, Kissei Pharmaceutical and Xbrane Biopharma.
The key targets in the Leiomyoma pipeline products market include Gonadotropin Releasing Hormone Receptor (GNRHR), Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR), and Estrogen Receptor (ESR).
The key mechanisms of action in the Leiomyoma pipeline product include Gonadotropin Releasing Hormone Receptor (GNRHR) Agonist with five drugs in Phase II. The Leiomyoma pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Leiomyoma pipeline products market including Small Molecule, and Synthetic Peptide.
Leiomyoma overview
A leiomyoma, also known as a fibroid, is a benign smooth muscle tumor that very rarely becomes cancer. They can occur in any organ, but the most common forms occur in the uterus, small bowel, and the esophagus. It commonly affects individuals between menarche and menopause.
For a complete picture of Leiomyoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
